Scarica l'app Stockscreener
263.61
1.70%
-4.56
Pre-mercato:
256.75
-6.86
-2.60%
Precedente Chiudi:
$268.17
Aprire:
$266.84
Volume 24 ore:
291.04K
Relative Volume:
1.29
Capitalizzazione di mercato:
$27.35B
Reddito:
$5.76B
Utile/perdita netta:
$514.49M
Rapporto P/E:
58.82
EPS:
4.4813
Flusso di cassa netto:
$1.10B
1 W Prestazione:
-5.52%
1M Prestazione:
-15.54%
6M Prestazione:
-18.31%
1 anno Prestazione:
+0.07%
Intervallo 1D:
$263.00
$271.59
Intervallo di 1 settimana:
$263.00
$283.75
Portata 52W:
$239.25
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Nome
Beone Medicines Ltd Adr
Settore
Industria
Telefono
41-616851900
Indirizzo
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
263.61 | 27.35B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
435.71 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
601.65 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.18 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.22 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.19 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Outperform |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Barclays | Overweight |
| 2025-04-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-12-03 | Ripresa | Morgan Stanley | Overweight |
| 2024-09-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-06 | Ripresa | JP Morgan | Overweight |
| 2023-09-12 | Iniziato | Macquarie | Outperform |
| 2023-08-17 | Iniziato | Jefferies | Buy |
| 2023-07-17 | Iniziato | Citigroup | Buy |
| 2023-06-30 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Iniziato | Daiwa Securities | Buy |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-10-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Ripresa | JP Morgan | Overweight |
| 2022-03-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Iniziato | Deutsche Bank | Buy |
| 2021-10-12 | Iniziato | Bernstein | Outperform |
| 2021-10-06 | Aggiornamento | CLSA | Underperform → Buy |
| 2021-03-08 | Iniziato | China Renaissance | Buy |
| 2021-03-01 | Downgrade | CLSA | Outperform → Underperform |
| 2020-11-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-06 | Downgrade | Piper Sandler | Neutral → Underweight |
Mostra tutto
Beone Medicines Ltd Adr Borsa (ONC) Ultime notizie
A Look At BeOne Medicines (ONC) Valuation After Analyst Upgrades And Positive ASCO 2026 Clinical Updates - Sahm
Capital International Sarl Raises Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines Ltd.Sponsored ADR $ONC Position Raised by Capital International Investors - MarketBeat
Is BeOne Medicines (ONC) Quietly Recasting Its Hematology Roots Into a Multi-Franchise Oncology Platform? - Sahm
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 - sharewise.com
ONC Technical Analysis | Trend, Signals & Chart Patterns | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Range Breakout - AASTOCKS.com
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Triangle Breakout - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 5.1M shares at $176.8, $901.68M turnover - AASTOCKS.com
BEONE MEDICINES (06160.HK) An Taisite Approved in Mainland China for Second-line Treatment of Small Cell Lung Cancer - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 254.9K shares at $175.1, $44.633M turnover - AASTOCKS.com
CICC: Focus on Positive Capital Flow Impact from Index Review on BEONE MEDICINES (06160.HK), J&T EXPRESS-W (01519.HK), KNOWLEDGE ATLAS (02513.HK) and MINIMAX-W (00100.HK) - AASTOCKS.com
Marriott Upgraded, Roku Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Bearish block trade of BEONE MEDICINES(06160) 231.3K shares at $185.8, $42.976M turnover - AASTOCKS.com
BeOne Medicines Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative - Sahm
HSI To Add J&T EXPRESS-W (01519.HK), CHALCO (02600.HK), BEONE MEDICINES (06160.HK) after Quarterly Review - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 212K shares at $184.5, $39.114M turnover - AASTOCKS.com
ONC Stock Price, Quote & Chart | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Ltd.: BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - FinanzNachrichten.de
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - Via TT
Bearish block trade of BEONE MEDICINES(06160) 323.6K shares at $183.1, $59.251M turnover - AASTOCKS.com
BeOne Medicines Wins FDA Nod For BEQALZI In Mantle Cell Lymphoma - Sahm
ONC News | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
Bearish block trade of BEONE MEDICINES(06160) 206.1K shares at $175.1, $36.088M turnover - AASTOCKS.com
BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer - Sahm
BeiGene Must Face AbbVie's Chemical Trade Secret Claims - Law360
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - ChartMill
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
Apple Upgraded, American Express Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BeOne Medicines (ONC) Is Up 7.4% After Guidance Hike And Priority Review Win In HER2 Cancer - Sahm
Citi Raises BeOne Medicines Ltd. (ONC.US) TP to USD453; 1Q26 Results Strong - AASTOCKS.com
Sigma Planning Corp Sells 3,208 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
UBS Group AG Grows Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BOCI: BEONE MEDICINES 1Q Results Beat; Rating Buy Reiterated - AASTOCKS.com
G Sachs Raises BeOne Medicines Ltd. (ONC.US) TP to USD414.46, Rating Buy - AASTOCKS.com
UBS Raises BeOne Medicines Ltd. (ONC.US) TP to USD465, 1Q Results Strong - AASTOCKS.com
M Stanley Raises BeOne Medicines Ltd. (ONC.US) TP to USD395; 1Q Results Beat Expectations - AASTOCKS.com
BeOne Medicines Q1 Earnings Call Highlights - Yahoo Finance
BeOne Medicines (ONC) registers 398.9M ordinary shares for resale by major holders - Stock Titan
BEONE MEDICINES (06160.HK) 1Q Net Profit USD227 million Surges 178x YoY; Raises FY2026 Revenue Guidance - AASTOCKS.com
Is It Too Late To Consider BeOne Medicines (ONC) After Its 23% One Year Gain? - Sahm
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy - Sahm
BeOne Medicines files 2025 annual report with Shanghai STAR Market - Investing.com
Oil Shock, AI Tailwinds, And Portfolio Shifts Across Emerging Markets - Seeking Alpha
Chan Henry Lee Sells 332 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Is BeOne (ONC) Stock entering maturity stage | ONC Q4 2025 Earnings: BeOne Medicines Ltd. ADS misses EPS, no revenue releasedADR - Newser
RBC Capital Adjusts Price Target on BeOne Medicines to $423 From $425, Maintains Outperform Rating - Moomoo
A Look At BeOne Medicines (ONC) Valuation After New Coverage And FDA Orphan Drug Designation - Sahm
BeOne Medicines (NASDAQ:ONC) Stock Price Down 6.2%Here's Why - MarketBeat
Beone Medicines Ltd Adr Azioni (ONC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
2.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):